{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:43:57Z","timestamp":1788295437368,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113004","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T04:39:02Z","timestamp":1725079142000},"page":"113004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity"],"prefix":"10.1016","volume":"142","author":[{"given":"Yanyan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiage","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2024.113004_b0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12882-021-02257-6","article-title":"PD-1 immunobiology in glomerulonephritis and renal cell carcinoma","volume":"22","author":"Curran","year":"2021","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113004_b0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"issue":"10267","key":"10.1016\/j.intimp.2024.113004_b0025","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0140-6736(20)32672-6","article-title":"PD-1 inhibitors for urothelial cancer: combination or sequential therapy?","volume":"396","author":"Zhang","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2024.113004_b0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2024.113004_b0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9948","key":"10.1016\/j.intimp.2024.113004_b0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2024.113004_b0050","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ymthe.2021.04.022","article-title":"Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19","volume":"29","author":"Capone","year":"2021","journal-title":"Mol. Ther."},{"issue":"115","key":"10.1016\/j.intimp.2024.113004_b0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"657","key":"10.1016\/j.intimp.2024.113004_b0060","article-title":"Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection","volume":"14","author":"D'Alise","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0065","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D'Alise","year":"2019","journal-title":"Nat. Commun."},{"issue":"627","key":"10.1016\/j.intimp.2024.113004_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj1996","article-title":"GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults","volume":"14","author":"Lanini","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113004_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"issue":"30","key":"10.1016\/j.intimp.2024.113004_b0080","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7\u2013H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.intimp.2024.113004_b0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13000-023-01320-0","article-title":"B7\u2013H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis","volume":"18","author":"Lee","year":"2023","journal-title":"Diagn. Pathol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113004_b0095","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","article-title":"B7\u2013H3 negatively modulates CTL-mediated cancer immunity","volume":"24","author":"Yonesaka","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.113004_b0100","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1159\/000447859","article-title":"B7\u2013H3 overexpression predicts poor survival of cancer patients: a meta-analysis","volume":"39","author":"Ye","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"issue":"14","key":"10.1016\/j.intimp.2024.113004_b0105","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.113004_b0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody-drug conjugate targeting B7\u2013H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.113004_b0115","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7\u2013H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.113004_b0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7\u2013H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2024.113004_b0130","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.113004_b0135","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"328","key":"10.1016\/j.intimp.2024.113004_b0140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113004_b0145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.molimm.2021.09.002","article-title":"Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma","volume":"139","author":"Sun","year":"2021","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113004_b0150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","article-title":"Checkpoint inhibitor immunotherapy in kidney cancer","volume":"17","author":"Xu","year":"2020","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113004_b0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113004_b0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12307-012-0127-6","article-title":"Effector CD4 and CD8 T cells and their role in the tumor microenvironment","volume":"6","author":"Hadrup","year":"2013","journal-title":"Cancer Microenviron."},{"issue":"10","key":"10.1016\/j.intimp.2024.113004_b0165","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1021\/acs.molpharmaceut.3c00330","article-title":"Controlling antigen fate in therapeutic cancer vaccines by targeting dendritic cell receptors","volume":"20","author":"Wijfjes","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.intimp.2024.113004_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113004_b0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri2368","article-title":"The known unknowns of antigen processing and presentation","volume":"8","author":"Vyas","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41541-023-00706-x","article-title":"The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma","volume":"8","author":"Jiang","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.intimp.2024.113004_b0185","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic cells and CD8 T cell immunity in tumor microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113004_b0190","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113004_b0195","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon gamma and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6024","key":"10.1016\/j.intimp.2024.113004_b0200","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","article-title":"Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy","volume":"51","author":"Zafar","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2024.113004_b0210","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/ph16101384","article-title":"Tumor vaccines: unleashing the power of the immune system to fight cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"10.1016\/j.intimp.2024.113004_b0215","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1073\/pnas.1722043115","article-title":"B7\u2013H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction","volume":"115","author":"Chen","year":"2018","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.intimp.2024.113004_b0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113004_b0225","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00262-020-02767-6","article-title":"The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors","volume":"70","author":"Scheuerpflug","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.intimp.2024.113004_b0230","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.drudis.2021.01.002","article-title":"Tumor-infiltrating CD8(+) T cell antitumor efficacy and exhaustion: molecular insights","volume":"26","author":"Kumar","year":"2021","journal-title":"Drug Discov. Today"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401525X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692401525X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:52:35Z","timestamp":1728010355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692401525X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S156757692401525X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113004","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113004"}}